Ablative strategies for recurrent hepatocellular carcinoma

doi:10.4254/wjh.v15.i4.515

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3917)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

123

WORD

HTML

2022

Tables (1-1)

283

Sum=2453

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

162

Download

500

Sum=662

Publishing Process of This Article

Item

Count

Browse

186

Download

501

Sum=687

Apr 27, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Apr 27, 2023; 15(4): 515-524
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.515

Table 1 Application of various minimally invasive treatments in hepatocellular carcinoma

Tumour size	Patients condition	Treatment
Sub-centimeter	Percutaneous tumors	PRFA
	Local ablation therapy is not feasible	TACE
< 3 cm	Percutaneous tumors	PRFA
	Subphrenic and subcapsular tumors	LRFA
	Perivascular tumors	MWA
	Can't endure thermal ablation	CRA
	MVI (+)	TACE-RFA
3-5 cm	With liver function compensation	TACE-RFA
	Liver failure	MWA, CRA

PRFA: Percutaneous radiofrequency ablation; LRFA: Laparoscopic radiofrequency ablation; TACE: Transarterial chemoembolization; MWA: Microwave ablation; CRA: Cryoablation; MVI: Microvascular invasion.

Citation: Wang L, Liu BX, Long HY. Ablative strategies for recurrent hepatocellular carcinoma. World J Hepatol 2023; 15(4): 515-524
URL: https://www.wjgnet.com/1948-5182/full/v15/i4/515.htm
DOI: https://dx.doi.org/10.4254/wjh.v15.i4.515